Adjuvant ICI for High-Risk MIUC: Patient Counseling
An expert discusses how medical professionals counsel eligible patients about adjuvant immune checkpoint inhibitor (ICI) therapy by discussing its potential to reduce cancer recurrence, emphasizing the benefits in high-risk cases. They carefully assess patient eligibility, explaining potential immune-related adverse events and balancing these risks with the treatment’s potential lifesaving benefits.
Video Player is loading.
Video content above is prompted by the following:
- How does availability of SC ICI impact treatment selection for your patients with bladder cancer? (NCCN 6.2024; Albiges 2025; Burotto 2024)
- In the advanced/metastatic setting
- In the perioperative setting
- From a practical standpoint, what potential cost and time savings could your center anticipate with SC ICI formulations?
- How might an SC option alleviate patient burden in treatment accessibility, compliance, and follow-up?
Recent Videos
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management
Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
MIUC: Risk of Recurrence After Radical Cystectomy
Related Content
